BACKGROUND: Prostaglandin analogs (PGAs) are considered an initial therapy to manage
increased intraocular pressure (IOP) for patients with glaucoma. When the initial PGA …

One of the most recent contributions to the therapeutic arsenal available for the treatment of
glaucoma is the prostaglandin (PG) analogues. They represent a new class of ocular …

Primary open-angle glaucoma (POAG) is a progressive optic neuropathy that, left untreated,
can lead to irreversible damage to the optic nerve and permanent vision loss. To date …

Glaucoma is a common eye condition that affects millions of individuals worldwide, making it
the second-leading cause of blindness. Because glaucoma is associated with increased IOP …

Glaucoma is a major cause of vision loss throughout the world. Treatment for glaucoma
consists of reducing intraocular pressure (IOP) to an acceptable target range to prevent …

Introduction Glaucoma is the leading cause of irreversible blindness worldwide. Medical
therapy is the main line of treatment of open-angle glaucoma (OAG) and ocular …

Topic. Prostaglandin analogues (PGAs) are first‐line medical therapy for primary open angle
glaucoma (POAG) and ocular hypertension (OHT). Intraocular pressure (IOP) lowering …

Over the last 12 years, the pharmacological management of glaucoma and ocular
hypertension has significantly changed with the introduction of the prostaglandin analogs …

Glaucoma causes irreversible vision loss, with elevated intraocular pressure (IOP) being the
only known modifiable risk factor. There are a variety of medical and interventional options …

Success of the long-term glaucoma therapy and preservation of the visual function strongly
depend on patients' compliance which may be affected by the inconvenience of treatment …